{
    "nctId": "NCT03255486",
    "briefTitle": "Identification and Evaluation of Biomarkers of Resistance to Neoadjuvant Chemotherapy (IDEA SEIN)",
    "officialTitle": "Identification and Evaluation of Biomarkers of Resistance to Neoadjuvant Chemotherapy and Establishment of Preclinical Models of Resistance in Locally Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 164,
    "primaryOutcomeMeasure": "predictive molecular abnormalities assessment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* proven invasive breast adenocarcinoma (cytology and / or biopsy).\n\n  * locally advanced stage (tumor size greater than 2 cm).\n  * neoadjuvant chemotherapy indication validated RCP\n  * Patient eligible for neoadjuvant chemotherapy.\n  * Performance Index according to WHO or less 1.\n  * Patient aged 18 years and older.\n  * Being affiliated to a social security scheme or an equivalent scheme of social protection\n  * Obtaining signed informed consent, and that before any specific prequalification testing.\n\nExclusion Criteria:\n\n* presence of metastatic disease at diagnosis.\n\n  * Breast Cancer inflammatory.\n  * rare histologic subtypes (non ductal lobular and not).\n  * Other cancer (except basal cell skin carcinoma and cancer of the cervix in situ adequately treated and curative) treated in the previous 5 years.\n  * Patient pregnant or nursing or of childbearing age without effective contraception.\n  * Breast cancer in men.\n  * legal incapacity or limited legal capacity. medical or psychological conditions allowing the subject to complete the study or to sign the consent (art. L.1121-6, L.1121-7, L.1211-8, L1211-9).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}